Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fausto Roila

Showing results (71-80 of 99) with videos related to

Pageof 10
Sort By:
Journal of Alternative and Complementary Medicine (New York, N.Y.)|April 27, 2016
Searching for Evidence to Support the Use of Ginger in the Prevention of Chemotherapy-Induced Nausea and VomitingPaolo Bossi, Diego Cortinovis, Maria Cossu Rocca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapyJørn Herrstedt, Wichit Apornwirat, Ahmed Shaharyar, et al.
Oncology and Therapy|November 16, 2023
Repotrectinib's Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung CancerGiulio Metro, Eleonora Gariazzo, Silvia Costabile, et al.
Clinical Lung Cancer|March 18, 2009
XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expressionRoberta Bartolucci, Jia Wei, Jose Javier Sanchez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASESteven Grunberg, Daniel Chua, Anish Maru, et al.
Oncology and Therapy|January 3, 2024
Correction: Repotrectinib's Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung CancerGiulio Metro, Eleonora Gariazzo, Silvia Costabile, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2005
The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trialsDavid G Warr, Steven M Grunberg, Richard J Gralla, et al.
Critical Reviews in Oncology/Hematology|September 18, 2017
Cognitive impairment and chemotherapy: a brief overviewMilena Vitali, Carla Ida Ripamonti, Fausto Roila, et al.
Diagnostics (Basel, Switzerland)|December 10, 2020
Detection of <i>EGFR</i> Mutations in Plasma Cell-Free Tumor DNA of TKI-Treated Advanced-NSCLC Patients by Three Methodologies: Scorpion-ARMS, PNAClamp, and Digital PCRAnnamaria Siggillino, Paola Ulivi, Luigi Pasini, et al.
Genes|August 19, 2020
Prevalence and Spectrum of <i>BRCA</i> Germline Variants in Central Italian High Risk or Familial Breast/Ovarian Cancer Patients: A Monocentric StudyJennifer Foglietta, Vienna Ludovini, Fortunato Bianconi, et al.
Pageof 10

Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
Journal of Alternative and Complementary Medicine (New York, N.Y.)|April 27, 2016
Searching for Evidence to Support the Use of Ginger in the Prevention of Chemotherapy-Induced Nausea and VomitingPaolo Bossi, Diego Cortinovis, Maria Cossu Rocca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapyJørn Herrstedt, Wichit Apornwirat, Ahmed Shaharyar, et al.
Oncology and Therapy|November 16, 2023
Repotrectinib's Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung CancerGiulio Metro, Eleonora Gariazzo, Silvia Costabile, et al.
Clinical Lung Cancer|March 18, 2009
XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expressionRoberta Bartolucci, Jia Wei, Jose Javier Sanchez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASESteven Grunberg, Daniel Chua, Anish Maru, et al.
Oncology and Therapy|January 3, 2024
Correction: Repotrectinib's Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung CancerGiulio Metro, Eleonora Gariazzo, Silvia Costabile, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2005
The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trialsDavid G Warr, Steven M Grunberg, Richard J Gralla, et al.
Critical Reviews in Oncology/Hematology|September 18, 2017
Cognitive impairment and chemotherapy: a brief overviewMilena Vitali, Carla Ida Ripamonti, Fausto Roila, et al.
Diagnostics (Basel, Switzerland)|December 10, 2020
Detection of <i>EGFR</i> Mutations in Plasma Cell-Free Tumor DNA of TKI-Treated Advanced-NSCLC Patients by Three Methodologies: Scorpion-ARMS, PNAClamp, and Digital PCRAnnamaria Siggillino, Paola Ulivi, Luigi Pasini, et al.
Genes|August 19, 2020
Prevalence and Spectrum of <i>BRCA</i> Germline Variants in Central Italian High Risk or Familial Breast/Ovarian Cancer Patients: A Monocentric StudyJennifer Foglietta, Vienna Ludovini, Fortunato Bianconi, et al.
Pageof 10